Loading…

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry

Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a pro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2019-02, Vol.8 (3), p.e010510
Main Authors: Goto, Shinya, Angchaisuksiri, Pantep, Bassand, Jean-Pierre, Camm, A John, Dominguez, Helena, Illingworth, Laura, Gibbs, Harry, Goldhaber, Samuel Z, Goto, Shinichi, Jing, Zhi-Cheng, Haas, Sylvia, Kayani, Gloria, Koretsune, Yukihiro, Lim, Toon Wei, Oh, Seil, Sawhney, Jitendra P S, Turpie, Alexander G G, van Eickels, Martin, Verheugt, Freek W A, Kakkar, Ajay K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643
cites cdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643
container_end_page
container_issue 3
container_start_page e010510
container_title Journal of the American Heart Association
container_volume 8
creator Goto, Shinya
Angchaisuksiri, Pantep
Bassand, Jean-Pierre
Camm, A John
Dominguez, Helena
Illingworth, Laura
Gibbs, Harry
Goldhaber, Samuel Z
Goto, Shinichi
Jing, Zhi-Cheng
Haas, Sylvia
Kayani, Gloria
Koretsune, Yukihiro
Lim, Toon Wei
Oh, Seil
Sawhney, Jitendra P S
Turpie, Alexander G G
van Eickels, Martin
Verheugt, Freek W A
Kakkar, Ajay K
description Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA DS - VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.
doi_str_mv 10.1161/JAHA.118.010510
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d158a0604f88404a9bba98c1831727c3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d158a0604f88404a9bba98c1831727c3</doaj_id><sourcerecordid>2179507733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</originalsourceid><addsrcrecordid>eNpVksFu1DAQhiMEolXpmRvykUtaO4ljhwNStG3ahYVWFQhxsibOZNdVEm9tb9E-Dy-Kt1uq1hePZv75xh79SfKe0RPGSnb6pb6sYyRPKKOc0VfJYUYLkVaVpK-fxQfJsfe3NJ4yEzmv3iYHORVMlKw8TP5-gwmWOOIUCEwdYelvBEeuNkHbET2xPbmGYGLZk18mrMh3_DNsyZmB5WQ9dqQOzsBAGtM6MwxRaqcH0Gzl7GQ0-Wq6CXcNHsHjJ3KDfjNEWOPsSMIKybWzfo06mHskF_VNMz9fnJGU1E2ULo0PbvsuedPD4PH48T5KfjbnP2aX6eLqYj6rF6nmlIe0A42s7TPW6x4YiopjCV0m-l53PVSV1sip1EXOUUjaChmrOhNdS6nOeVnkR8l8z-0s3Kq1MyO4rbJg1EPCuqUCF4weUHWMS6AlLXopC1pA1bZQSc1kzkQmdB5Zn_es9aYdsdNxgQ6GF9CXlcms1NLeq7KgnFdlBHx8BDh7t0Ef1Gi8xrjiCe3Gq4zFD1Ih8t2s071Ux1V6h_3TGEbVzilq55QYSbV3Suz48Px1T_r_vsj_AeH8uvM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179507733</pqid></control><display><type>article</type><title>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</title><source>PubMed Central(OpenAccess)</source><source>Wiley Open Access</source><creator>Goto, Shinya ; Angchaisuksiri, Pantep ; Bassand, Jean-Pierre ; Camm, A John ; Dominguez, Helena ; Illingworth, Laura ; Gibbs, Harry ; Goldhaber, Samuel Z ; Goto, Shinichi ; Jing, Zhi-Cheng ; Haas, Sylvia ; Kayani, Gloria ; Koretsune, Yukihiro ; Lim, Toon Wei ; Oh, Seil ; Sawhney, Jitendra P S ; Turpie, Alexander G G ; van Eickels, Martin ; Verheugt, Freek W A ; Kakkar, Ajay K</creator><creatorcontrib>Goto, Shinya ; Angchaisuksiri, Pantep ; Bassand, Jean-Pierre ; Camm, A John ; Dominguez, Helena ; Illingworth, Laura ; Gibbs, Harry ; Goldhaber, Samuel Z ; Goto, Shinichi ; Jing, Zhi-Cheng ; Haas, Sylvia ; Kayani, Gloria ; Koretsune, Yukihiro ; Lim, Toon Wei ; Oh, Seil ; Sawhney, Jitendra P S ; Turpie, Alexander G G ; van Eickels, Martin ; Verheugt, Freek W A ; Kakkar, Ajay K ; GARFIELD‐AF Investigators</creatorcontrib><description>Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA DS - VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.</description><identifier>ISSN: 2047-9980</identifier><identifier>EISSN: 2047-9980</identifier><identifier>DOI: 10.1161/JAHA.118.010510</identifier><identifier>PMID: 30717616</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants - administration &amp; dosage ; Asia - epidemiology ; atrial fibrillation ; Atrial Fibrillation - complications ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - mortality ; chronic kidney disease ; Female ; Follow-Up Studies ; GARFIELD‐AF registry ; Humans ; Incidence ; Male ; Middle Aged ; Original Research ; outcomes research ; Prognosis ; Prospective Studies ; Registries ; registry ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - mortality ; Renal Insufficiency, Chronic - therapy ; Risk Assessment - methods ; Risk Factors ; Severity of Illness Index ; Stroke - epidemiology ; Stroke - etiology ; Stroke - prevention &amp; control ; Survival Rate - trends ; Time Factors</subject><ispartof>Journal of the American Heart Association, 2019-02, Vol.8 (3), p.e010510</ispartof><rights>2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</citedby><cites>FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405596/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405596/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30717616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goto, Shinya</creatorcontrib><creatorcontrib>Angchaisuksiri, Pantep</creatorcontrib><creatorcontrib>Bassand, Jean-Pierre</creatorcontrib><creatorcontrib>Camm, A John</creatorcontrib><creatorcontrib>Dominguez, Helena</creatorcontrib><creatorcontrib>Illingworth, Laura</creatorcontrib><creatorcontrib>Gibbs, Harry</creatorcontrib><creatorcontrib>Goldhaber, Samuel Z</creatorcontrib><creatorcontrib>Goto, Shinichi</creatorcontrib><creatorcontrib>Jing, Zhi-Cheng</creatorcontrib><creatorcontrib>Haas, Sylvia</creatorcontrib><creatorcontrib>Kayani, Gloria</creatorcontrib><creatorcontrib>Koretsune, Yukihiro</creatorcontrib><creatorcontrib>Lim, Toon Wei</creatorcontrib><creatorcontrib>Oh, Seil</creatorcontrib><creatorcontrib>Sawhney, Jitendra P S</creatorcontrib><creatorcontrib>Turpie, Alexander G G</creatorcontrib><creatorcontrib>van Eickels, Martin</creatorcontrib><creatorcontrib>Verheugt, Freek W A</creatorcontrib><creatorcontrib>Kakkar, Ajay K</creatorcontrib><creatorcontrib>GARFIELD‐AF Investigators</creatorcontrib><title>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</title><title>Journal of the American Heart Association</title><addtitle>J Am Heart Assoc</addtitle><description>Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA DS - VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>Asia - epidemiology</subject><subject>atrial fibrillation</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - mortality</subject><subject>chronic kidney disease</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>GARFIELD‐AF registry</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Research</subject><subject>outcomes research</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>registry</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - mortality</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Stroke - epidemiology</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention &amp; control</subject><subject>Survival Rate - trends</subject><subject>Time Factors</subject><issn>2047-9980</issn><issn>2047-9980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksFu1DAQhiMEolXpmRvykUtaO4ljhwNStG3ahYVWFQhxsibOZNdVEm9tb9E-Dy-Kt1uq1hePZv75xh79SfKe0RPGSnb6pb6sYyRPKKOc0VfJYUYLkVaVpK-fxQfJsfe3NJ4yEzmv3iYHORVMlKw8TP5-gwmWOOIUCEwdYelvBEeuNkHbET2xPbmGYGLZk18mrMh3_DNsyZmB5WQ9dqQOzsBAGtM6MwxRaqcH0Gzl7GQ0-Wq6CXcNHsHjJ3KDfjNEWOPsSMIKybWzfo06mHskF_VNMz9fnJGU1E2ULo0PbvsuedPD4PH48T5KfjbnP2aX6eLqYj6rF6nmlIe0A42s7TPW6x4YiopjCV0m-l53PVSV1sip1EXOUUjaChmrOhNdS6nOeVnkR8l8z-0s3Kq1MyO4rbJg1EPCuqUCF4weUHWMS6AlLXopC1pA1bZQSc1kzkQmdB5Zn_es9aYdsdNxgQ6GF9CXlcms1NLeq7KgnFdlBHx8BDh7t0Ef1Gi8xrjiCe3Gq4zFD1Ih8t2s071Ux1V6h_3TGEbVzilq55QYSbV3Suz48Px1T_r_vsj_AeH8uvM</recordid><startdate>20190205</startdate><enddate>20190205</enddate><creator>Goto, Shinya</creator><creator>Angchaisuksiri, Pantep</creator><creator>Bassand, Jean-Pierre</creator><creator>Camm, A John</creator><creator>Dominguez, Helena</creator><creator>Illingworth, Laura</creator><creator>Gibbs, Harry</creator><creator>Goldhaber, Samuel Z</creator><creator>Goto, Shinichi</creator><creator>Jing, Zhi-Cheng</creator><creator>Haas, Sylvia</creator><creator>Kayani, Gloria</creator><creator>Koretsune, Yukihiro</creator><creator>Lim, Toon Wei</creator><creator>Oh, Seil</creator><creator>Sawhney, Jitendra P S</creator><creator>Turpie, Alexander G G</creator><creator>van Eickels, Martin</creator><creator>Verheugt, Freek W A</creator><creator>Kakkar, Ajay K</creator><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190205</creationdate><title>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</title><author>Goto, Shinya ; Angchaisuksiri, Pantep ; Bassand, Jean-Pierre ; Camm, A John ; Dominguez, Helena ; Illingworth, Laura ; Gibbs, Harry ; Goldhaber, Samuel Z ; Goto, Shinichi ; Jing, Zhi-Cheng ; Haas, Sylvia ; Kayani, Gloria ; Koretsune, Yukihiro ; Lim, Toon Wei ; Oh, Seil ; Sawhney, Jitendra P S ; Turpie, Alexander G G ; van Eickels, Martin ; Verheugt, Freek W A ; Kakkar, Ajay K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>Asia - epidemiology</topic><topic>atrial fibrillation</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - mortality</topic><topic>chronic kidney disease</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>GARFIELD‐AF registry</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Research</topic><topic>outcomes research</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>registry</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - mortality</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Stroke - epidemiology</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention &amp; control</topic><topic>Survival Rate - trends</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goto, Shinya</creatorcontrib><creatorcontrib>Angchaisuksiri, Pantep</creatorcontrib><creatorcontrib>Bassand, Jean-Pierre</creatorcontrib><creatorcontrib>Camm, A John</creatorcontrib><creatorcontrib>Dominguez, Helena</creatorcontrib><creatorcontrib>Illingworth, Laura</creatorcontrib><creatorcontrib>Gibbs, Harry</creatorcontrib><creatorcontrib>Goldhaber, Samuel Z</creatorcontrib><creatorcontrib>Goto, Shinichi</creatorcontrib><creatorcontrib>Jing, Zhi-Cheng</creatorcontrib><creatorcontrib>Haas, Sylvia</creatorcontrib><creatorcontrib>Kayani, Gloria</creatorcontrib><creatorcontrib>Koretsune, Yukihiro</creatorcontrib><creatorcontrib>Lim, Toon Wei</creatorcontrib><creatorcontrib>Oh, Seil</creatorcontrib><creatorcontrib>Sawhney, Jitendra P S</creatorcontrib><creatorcontrib>Turpie, Alexander G G</creatorcontrib><creatorcontrib>van Eickels, Martin</creatorcontrib><creatorcontrib>Verheugt, Freek W A</creatorcontrib><creatorcontrib>Kakkar, Ajay K</creatorcontrib><creatorcontrib>GARFIELD‐AF Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Journal of the American Heart Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goto, Shinya</au><au>Angchaisuksiri, Pantep</au><au>Bassand, Jean-Pierre</au><au>Camm, A John</au><au>Dominguez, Helena</au><au>Illingworth, Laura</au><au>Gibbs, Harry</au><au>Goldhaber, Samuel Z</au><au>Goto, Shinichi</au><au>Jing, Zhi-Cheng</au><au>Haas, Sylvia</au><au>Kayani, Gloria</au><au>Koretsune, Yukihiro</au><au>Lim, Toon Wei</au><au>Oh, Seil</au><au>Sawhney, Jitendra P S</au><au>Turpie, Alexander G G</au><au>van Eickels, Martin</au><au>Verheugt, Freek W A</au><au>Kakkar, Ajay K</au><aucorp>GARFIELD‐AF Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry</atitle><jtitle>Journal of the American Heart Association</jtitle><addtitle>J Am Heart Assoc</addtitle><date>2019-02-05</date><risdate>2019</risdate><volume>8</volume><issue>3</issue><spage>e010510</spage><pages>e010510-</pages><issn>2047-9980</issn><eissn>2047-9980</eissn><abstract>Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ). Methods and Results GARFIELD - AF is a prospective registry of patients from 35 countries, including patients from Asia (China, India, Japan, Singapore, South Korea, and Thailand). Consecutive patients enrolled (2013-2016) were classified with no, mild, or moderate-to-severe CKD , based on the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines. Data on CKD status and outcomes were available for 33 024 of 34 854 patients (including 9491 patients from Asia); 10.9% (n=3613) had moderate-to-severe CKD , 16.9% (n=5595) mild CKD , and 72.1% (n=23 816) no CKD . The use of oral anticoagulants was influenced by stroke risk (ie, post hoc assessment of CHA DS - VAS c score), but not by CKD stage. The quality of anticoagulant control with vitamin K antagonists did not differ with CKD stage. After adjusting for baseline characteristics and antithrombotic use, both mild and moderate-to-severe CKD were independent risk factors for all-cause mortality. Moderate-to-severe CKD was independently associated with a higher risk of stroke/systemic embolism, major bleeding, new-onset acute coronary syndrome, and new or worsening heart failure. The impact of moderate-to-severe CKD on mortality was significantly greater in patients from Asia than the rest of the world ( P=0.001). Conclusions In GARFIELD - AF , moderate-to-severe CKD was independently associated with stroke/systemic embolism, major bleeding, and mortality. The effect of moderate-to-severe CKD on mortality was even greater in patients from Asia than the rest of the world. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01090362.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>30717616</pmid><doi>10.1161/JAHA.118.010510</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9980
ispartof Journal of the American Heart Association, 2019-02, Vol.8 (3), p.e010510
issn 2047-9980
2047-9980
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d158a0604f88404a9bba98c1831727c3
source PubMed Central(OpenAccess); Wiley Open Access
subjects Administration, Oral
Aged
Aged, 80 and over
Anticoagulants - administration & dosage
Asia - epidemiology
atrial fibrillation
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Atrial Fibrillation - mortality
chronic kidney disease
Female
Follow-Up Studies
GARFIELD‐AF registry
Humans
Incidence
Male
Middle Aged
Original Research
outcomes research
Prognosis
Prospective Studies
Registries
registry
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - mortality
Renal Insufficiency, Chronic - therapy
Risk Assessment - methods
Risk Factors
Severity of Illness Index
Stroke - epidemiology
Stroke - etiology
Stroke - prevention & control
Survival Rate - trends
Time Factors
title Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A58%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20and%201-Year%20Outcomes%20of%20Patients%20With%20Newly%20Diagnosed%20Atrial%20Fibrillation%20and%20Chronic%20Kidney%20Disease:%20Results%20From%20the%20Prospective%20GARFIELD%20-%20AF%20Registry&rft.jtitle=Journal%20of%20the%20American%20Heart%20Association&rft.au=Goto,%20Shinya&rft.aucorp=GARFIELD%E2%80%90AF%20Investigators&rft.date=2019-02-05&rft.volume=8&rft.issue=3&rft.spage=e010510&rft.pages=e010510-&rft.issn=2047-9980&rft.eissn=2047-9980&rft_id=info:doi/10.1161/JAHA.118.010510&rft_dat=%3Cproquest_doaj_%3E2179507733%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-dace1bf21fcfa1e795e6ad27ffcdfa99cce508c435e780b786adc27db00c35643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2179507733&rft_id=info:pmid/30717616&rfr_iscdi=true